ArticleClinical and molecular hepatology2026

Rethinking first-line screening in MASLD beyond the limitations of Fibrosis-4 index: Editorial on "Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease".

Han Ah Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.